Recent News

• 01.28.2026 - PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
• 01.22.2026 - PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
• 01.09.2026 - PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
• 11.11.2025 - PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
• 11.10.2025 - PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Recent Filings

• 01.22.2026 - 8-K Current report
• 01.22.2026 - EX-99.1 EX-99.1
• 01.09.2026 - 8-K Current report
• 01.09.2026 - EX-99.1 EX-99.1
• 12.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 12.09.2025 - EX-99.1 EX-99.1
• 12.09.2025 - 8-K Current report
• 12.02.2025 - 8-K Current report
• 12.02.2025 - EX-99.1 EX-99.1
• 11.13.2025 - EX-99.1 EX-99.1